UK cancer mutation testing firm Biofidelity raises $12m
pharmaphorum
AUGUST 21, 2020
Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Both previously worked at Cambridge-based DNA sequencing specialist Base4 Innovation, where the technology was developed.
57 
Let's personalize your content